Federal Register / Vol. 72, No. 147 / Wednesday, August 1, 2007 / Notices 42099 

allocated in accordance with section 

2604 of the Act and must be treated by 

LIHEAP grantees receiving them as an 

amount appropriated for FY 2007. As 

FY 2007 funds, they will be subject to 

all requirements of the Act, including 

section 2607(b)(2), which requires that a 

grantee obligate at least 90 percent of its 

total block grant allocation for a fiscal 

year by the end of the fiscal year for 

which the funds are appropriated, that 

is, by September 30, 2007. 

FOR FURTHER INFORMATION CONTACT: Nick 

St. Angelo, Director, Division of Energy 

Assistance, Office of Community 

Services, 370 L’Enfant Promenade, SW., 

Washington, DC 20447; telephone (202) 

401–9351. 

Dated: July 26, 2007. 

Yolanda J. Butler, 

Deputy Director, Office of Community 

Services. 

[FR Doc. E7–14875 Filed 7–31–07; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Filovirus Animal Models; Public 

Workshop 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice of public workshop. 

The National Institutes of Health 

(NIH) is announcing a public workshop 

entitled: Filoviruses: Current Status of 

Research into Pathophysiology and 

Potential Uses of Animal Models. The 

purpose of the public workshop is to 

discuss the current state of 

understanding of filovirus infections, 

knowledge gaps and research needs, the 

current status of research exploring 

animal models, and the potential role of 

model development in approaches to 

investigation of therapeutic or vaccine 

strategies directed towards filoviruses. 

DATE AND TIME: The public workshop 

will be held on September 11, 2007 

from 8:30 a.m.–5 p.m. and on September 

12, 2007 from 8:30 a.m.–1 p.m. 

LOCATION: The public workshop will be 

held at the main auditorium, Natcher 

Conference Center, NIH Campus, 45 

Center Drive, Bethesda, Maryland. 

CONTACT PERSON: Ping Chen, 6610 

Rockledge Drive, telephone: 301–451–

3756, fax: 301–480–1263, e-mail: 

chenpi@niaid.nih.gov 

REGISTRATION: Pre-registration is 

required and must be completed by 

August 24, 2007. Please go to the 

following web site for information about 

registration (http://www.niaid.nih.gov/ 

news/events/meetings/filo/). There is no 

registration fee for the public workshop. 

Early registration is recommended 

because seating is limited. There will be 

no onsite registration. 

If you need special accommodations 

due to a disability, please contact (see 

Contact Person) at least 7 days in 

advance. 

SUPPLEMENTARY INFORMATION: NIH, CDC, 

DoD, and FDA, are cosponsoring a 

public workshop titled, ‘‘Filoviruses: 

Current Status of Research into 

Pathophysiology and Potential Uses of 

Animal Models’’. The meeting will 

discuss: (1) Background information on 

filovirus pathogenesis and clinical 

disease in humans and animals, and 

status of research into the 

understanding of human disease and 

development of animal models; (2) 

Background information on the 

scientific issues and regulatory 

approaches to the potential uses of 

animal data in the development of 

prevention and treatment strategies; (3) 

General review of filovirus vaccine 

design, rationale, and correlates of 

protection; (4) General review of the 

status of preliminary research 

approaches to filovirus-directed 

antiviral therapeutics. The workshop’s 

goal is to enhance understanding of 

filovirus disease, identify knowledge 

gaps and research needs, and explore 

the potential strengths and limitations 

of various animal models. 

TRANSCRIPTS: Transcripts of the public 

workshop will be available following 

the workshop. Procedures to obtain a 

transcript will be made available at a 

later date. 

Dated: July 23, 2007. 

Michael G. Kurilla, 

Director, Office of Biodefense Research 

Affairs, Associate Director for Biodefense 

Product Development, DMID, NIAID, National 

Institutes of Health. 

[FR Doc. E7–14874 Filed 7–31–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Delegation of Authority 

Notice is hereby given that I have 

delegated to the Director, National 

Institutes of Health (NIH), the 

authorities under section 3 of Public 

Law 109–416 (Combating Autism Act of 

2006), which amends Title III of the 

Public Health Service Act, by adding 

Part R, section 399CC, authorizing 

establishment of the Interagency Autism 

Coordinating Committee. I am also 

delegating the authority under Title III, 

section 399CC of the Public Health 

Service Act, as amended, to select 

Federal members of the Committee, 

including the chair, as appropriate. I 

will retain the authority under Title III, 

section 399CC(c)(2), pertaining to the 

selection of additional non-Federal 

public members of the Committee. 

This delegation excludes the authority 

to submit reports to the Congress, and 

shall be exercised in accordance with 

the Department’s applicable policies, 

procedures, and guidelines relating to 

regulations. 

This delegation is effective upon 

signature. In addition, I ratified and 

affirmed any actions taken by the 

Director of the NIH or his subordinates 

which involved the exercise of the 

authorities delegated herein prior to the 

effective date of the delegation. 

This delegation was effective upon 

date of signature. 

Dated: July 18, 2007. 

Michael O. Leavitt, 

Secretary. 

[FR Doc. 07–3735 Filed 7–31–07; 8:45 am] 

BILLING CODE 4160–18–M 

DEPARTMENT OF HOUSING AND 

URBAN DEVELOPMENT 

[Docket No. FR–5155–N–01] 

Mortgage and Loan Insurance 

Programs Under the National Housing 

Act—Debenture Interest Rates 

AGENCY: Office of the Assistant 

Secretary for Housing—Federal Housing 

Commissioner, HUD. 

ACTION: Notice. 

SUMMARY: This notice announces 

changes in the interest rates to be paid 

on debentures issued with respect to a 

loan or mortgage insured by the Federal 

Housing Administration under the 

provisions of the National Housing Act 

(the Act). The interest rate for 

debentures issued under section 

221(g)(4) of the Act during the 6-month 

period beginning July 1, 2007, is 43⁄4

percent. The interest rate for debentures 

issued under any other provision of the 

Act is the rate in effect on the date that 

the commitment to insure the loan or 

mortgage was issued, or the date that the 

loan or mortgage was endorsed (or 

initially endorsed if there are two or 

more endorsements) for insurance, 

whichever rate is higher. The interest 

rate for debentures issued under these 

other provisions with respect to a loan 

or mortgage committed or endorsed 

during the 6-month period beginning 


jlentini on PROD1PC65 with NOTICES